Imatinib

Imatinib is a selective BCR-ABL tyrosine kinase inhibitor used in the treatment of Philadelphia chromosome-positive CML and gastrointestinal stromal tumors (GIST). It was the first targeted molecular therapy for CML. Mediocon Inc supplies pharmaceutical-grade Imatinib Mesylate API meeting IP/BP/EP/USP standards.

Key Features

• First-in-class BCR-ABL TKI
• IP/BP/EP/USP compliant quality
• Selective kinase inhibition (BCR-ABL, c-KIT, PDGFR)
• High purity >99% by HPLC

Applications

• Philadelphia chromosome-positive CML
• Gastrointestinal stromal tumors (GIST)
• Acute lymphoblastic leukemia (ALL)
• Dermatofibrosarcoma protuberans

Why Choose Mediocon

• ISO 9001:2015 & GMP certified manufacturing
• Consistent batch-to-batch quality with full CoA
• Export-ready documentation: COO, MSDS, DMF
• Flexible MOQ for both R&D and commercial scale
• Dedicated QA support for regulatory filings